Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels

Clinical Cancer Research

Volumn 14, Issue 19, 2008, Pages 6330-6335

  Geisler, Jürgen ^a   Helle, Hilgegunn ^b,c   Ekse, Dagfinn ^b,c   Duong, Nhat K ^b,c   Evans, Dean B ^d   Nordbø, Yngve ^c   Aas, Turid ^c   Lønning, Per E ^b,c  

^a AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ESTRADIOL; ESTRONE; ESTRONE SULFATE; LETROZOLE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; ESTROGEN; NITRILE; TRIAZOLE DERIVATIVE;

ADULT; AGED; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ESTROGEN BLOOD LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; POSTMENOPAUSE; PRIORITY JOURNAL; BLOOD; BREAST TUMOR; COMPARATIVE STUDY; METABOLISM; MIDDLE AGED; RADIOIMMUNOASSAY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ESTRADIOL; ESTROGENS; ESTRONE; FEMALE; HUMANS; MIDDLE AGED; NITRILES; POSTMENOPAUSE; RADIOIMMUNOASSAY; TRIAZOLES;

EID: 58149145625     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-5221     Document Type: Article

References (50)

1. Bonneterre J, Buzdar A, Nabholtz JM, et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 2001;92:2247-58.
2. Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001;19:2596-606.
3. Paridaens R, Dirix L, Beex L, et al. Promising results with exemestane in the first-line treatment of metastatic breast cancer: a randomized phase II EORTC trial with a tamoxifen control. Clin Breast Cancer 2000;1 Suppl 1:S19-21.
4. Thürlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353:2747-57.
5. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081-92.
6. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:60-2.
7. Dowsett M, Jones A, Johnston SR, Jacobs S, Trunet P, Smith IE. In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer. Clin Cancer Res 1995;1:1511-5.
8. Geisler J, King N, Dowsett M, et al. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Br J Cancer 1996;74:1286-91.
9. Geisler J, King N, Anker G, et al. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin Cancer Res 1998;4:2089-93.
10. Geisler J, Haynes B, Anker G, Dowsett M, Lønning PE. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 2002;20:751-7.
11. MacNeill FA, Jones AL, Jacobs S, Lønning PE, Powles TJ, Dowsett M. The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer. Br J Cancer 1992;66:692-7.
12. Jones AL, MacNeill F, Jacobs S, Lønning PE, Dowsett M, Powles TJ. The influence of intramuscular 4-hydroxyandrostenedione on peripheral aromatisation in breast cancer patients. Eur J Cancer 1992;28A:1712-6.
13. MacNeill FA, Jacobs S, Dowsett M, Lønning PE, Powles TJ. The effects of oral 4-hydroxyandrostenedione on peripheral aromatisation in post-menopausal breast cancer patients. Cancer Chemother Pharmacol 1995;36:249-54.
14. Lønning PE, Jacobs S, Jones A, Haynes B, Powles T, Dowsett M. The influence of CGS 16949A on peripheral aromatisation in breast cancer patients. Br J Cancer 1991;63:789-93.
15. Lønning PE. Aromatase inhibitors in breast cancer. Endocr Relat Cancer 2004;11:179-89.
16. Brodie A, Long B. Aromatase inhibition and inactivation. Clin Cancer Res 2001;7:4343-9s; discussion 411-412s.
17. Chen S, Masri S, Wang X, Phung S, Yuan YC, Wu X. What do we know about the mechanisms of aromatase inhibitor resistance? J Steroid Biochem Mol Biol 2006;102:232-40.
18. Lønning PE, Bajetta E, Murray R, et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. J Clin Oncol 2000;18:2234-44.
19. Thürlimann B, Paridaens R, Serin D, et al. Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. Exemestane Study Group. Eur J Cancer 1997;33:1767-73.
20. Carlini P, Michelotti A, Ferretti G, et al. Clinical evaluation of the use of exemestane as further hormonal therapy after nonsteroidal aromatase inhibitors in postmenopausal metastatic breast cancer patients. Cancer Invest 2007;25:102-5.
21. Bertelli G. Sequencing of aromatase inhibitors. Br J Cancer 2005;93 (Suppl 1):S6-9.
22. Lønning PE. Comparison between aromatase inhibitors and sequential use. J Steroid Biochem Mol Biol 2003;86:275-82.
23. Rose C, Vtoraya O, Pluzanska A, et al. An open randomised trial of second-line endocrine therapy in advanced breast cancer. comparison of the aromatase inhibitors letrozole and anastrozole. Eur J Cancer 2003;39:2318-27.
24. Geisler J. Breast cancer tissue estrogens and their manipulation with aromatase inhibitors and inactivators. J Steroid Biochem Mol Biol 2003;86:245-53.
25. Miller WR, Mullen P, Telford J, Dixon JM. Clinical importance of intratumoral aromatase. Breast Cancer Res Treat 1998;49 Suppl 1:S27-32; discussion S3-7.
26. Reed MJ, Owen AM, Lai LC, et al. In situ oestrone synthesis in normal breast and breast tumour tissues: effect of treatment with 4-hydroxyandrostenedione. Int J Cancer 1989;44:233-7.
27. Miller WR, Telford J, Love CD, et al. Effects of letrozole as primary medical therapy on in situ oestrogen synthesis and endogenous oestrogen levels within the breast. The Breast 1998;7:273-6.
28. de Jong PC, van de Ven J, Nortier HW, et al. Inhibition of breast cancer tissue aromatase activity and estrogen concentrations by the third-generation aromatase inhibitor vorozole. Cancer Res 1997;57:2109-11.
29. Geisler J, Berntsen H, Lønning PE. A novel HPLC-RIA method for the simultaneous detection of estrone, estradiol and estrone sulphate levels in breast cancer tissue. J Steroid Biochem Mol Biol 2000;72:259-64.
30. Geisler J, Detre S, Berntsen H, et al. Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer. Clin Cancer Res 2001;7:1230-6.
31. Geisler J, Ekse D, Helle H, Duong NK, Lønning PE. An optimised, highly sensitive radioimmunoassay for the simultaneous measurement of estrone, estradiol and estrone sulfate in the ultra-low range in human plasma samples. J Steroid Biochem Mol Biol 2008;109:90-5.
32. Lønning PE, Helle SI, Johannessen DC, et al. Relations between sex hormones, sex hormone binding globulin, insulin-like growth factor-I and insulin-like growth factor binding protein-1 in post-menopausal breast cancer patients. Clin Endocrinol (Oxf) 1995;42:23-30.
33. Lønning PE, Ekse D. A sensitive assay for measurement of plasma estrone sulphate in patients on treatment with aromatase inhibitors. J Steroid Biochem Mol Biol 1995;55:409-12.
34. Geisler J, Lønning PE. Aromatase inhibition: translation into a successful therapeutic approach. Clin Cancer Res 2005;11:2809-21.
35. Baum M, Buzdar A, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003;98:1802-10.
36. Masamura S, Santner SJ, Gimotty P, George J, Santen RJ. Mechanism for maintenance of high breast tumor estradiol concentrations in the absence of ovarian function: role of very high affinity tissue uptake. Breast Cancer Res Treat 1997;42:215-26.
37. Miller WR, Hawkins RA, Forrest AP. Significance of aromatase activity in human breast cancer. Cancer Res1982;42:3365-8s.
38. Miller WR, Mullen P, Sourdaine P, Watson C, Dixon JM, Telford J. Regulation of aromatase activity within the breast. J Steroid Biochem Mol Biol 1997;61:193-202.
39. Simpson ER. Sources of estrogen and their importance. J Steroid Biochem Mol Biol 2003;86:225-30.
40. Honma N, Takubo K, Sawabe M, et al. Estrogen-metabolizing enzymes in breast cancers from women over the age of 80 years. J Clin Endocrinol Metab 2006;91:607-13.
41. Sasano H, Suzuki T, Nakata T, Moriya T. New development in intracrinology of breast carcinoma. Breast Cancer 2006;13:129-36.
42. Folkerd EJ, Martin LA, Kendall A, Dowsett M. The relationship between factors affecting endogenous oestradiol levels in postmenopausal women and breast cancer. J Steroid Biochem Mol Biol 2006;102:250-5.
43. Berstein LM, Kovalevskij AY, Poroshina TE, et al. Signs of proinflammatory/genotoxic switch (adipogenotoxicosis) in mammary fat of breast cancer patients: role of menopausal status, estrogens and hyperglycemia. Int J Cancer 2007;121:514-9.
44. Miki Y, Suzuki T, Tazawa C, et al. Aromatase localization in human breast cancer tissues: possible interactions between intratumoral stromal and parenchymal cells. Cancer Res 2007;67:3945-54.
45. Suzuki T, Miki Y, Nakamura Y, et al. Sex steroid-producing enzymes in human breast cancer. Endocr Relat Cancer 2005;12:701-20.
46. Santen RJ. Determinants of tissue oestradiol levels in human breast cancer. Cancer Surv 1986;5:597-616.
47. Miller WR, Dixon JM. Local endocrine effects of aromatase inhibitors within the breast. J Steroid Biochem Mol Biol 2001;79:93-102.
48. James VH, Reed MJ, Lai LC, et al. Regulation of estrogen concentrations in human breast tissues. Ann N Y Acad Sci 1990;595:227-35.
49. Masamura S, Santner SJ, Heitjan DF, Santen RJ. Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. J Clin Endocrinol Metab 1995;80:2918-25.
50. Sabnis G, Jelovac D, Long B, Brodie A. The role of growth factor receptor pathways in human breast cancer cells adapted to long-term estrogen deprivation. Cancer Res 2005;65:3903-10.